Johnson & Johnson Division Inks Exclusive Agreement with POZEN (POZN) to License Migraine Treatment in Latin America

QualityStocks would like to highlight POZEN Inc. (NASDAQ: POZN), a progressive pharmaceutical company that is transforming how the healthcare industry addresses unmet medical needs. By utilizing a unique in-source model and a focus on integrated therapies, POZEN has successfully developed and obtained FDA approval of two self-invented products in two years - something almost no other small pharmaceutical company has done.

In the company’s news yesterday,

POZEN announced that it has entered into a license agreement with Cilag GmbH International, a division of Johnson & Johnson (NYSE: JNJ), to develop and commercialize POZEN’s proprietary migraine treatment in Brazil, Columbia, Ecuador and Peru.

Per the agreement, Cilag holds an exclusive license to manufacture, develop and commercialize MT 400 in the noted territories. POZEN previously licensed the U.S.-only rights of MT 400 to GlaxoSmithKline, who markets a different dose of the drug under the name Treximet®.

“We are pleased to have reached an agreement with Cilag to develop and commercialize MT 400 in several countries in Latin America,” Liz Cermak, executive vice president and CEO of POZEN stated in the press release. “This is a first step in bringing this novel migraine product to the millions of migraine patients living outside of the United States. In addition, the income from this deal will help fuel the development and commercialization of our integrated aspirin ‘PA’ portfolio of products.”

Under the new deal, Cilag will make an upfront payment to POZEN, followed by a milestone payment to POZEN once MT400 is approved by the National Health Surveillance Agency of Brazil. During the first 10 years of sales, Cilag will pay POZEN a high single-digit royalty on net sales of MT 400, followed by a low single digit royalty during the next five years.

POZEN said the agreement will expire on a country-by-country basis on the 15th anniversary of the first commercial sale of MT 400 in each country.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.